CoChat

The DOI matches its Crossref record.

The Putative Use of Lithium in Alzheimer's Disease

Morris, Gerwyn, Berk, Michael · 2016 · Current Alzheimer Research

Abstract

Alzheimer`s disease is a progressive neurodegenerative illness characterized by the invariant existence of β-amyloid plaques and neurofibrillary tangles. Presently approved pharmaceutical approaches offer only marginal efficacy and as yet there is no effective treatment which reverses or arrests the disease. Thus far, drugs targeting any single aspect of disease pathology have proved to be a failure or at best provided very slight clinical benefit. The consistent failure of drugs targeting aspects of the Aβ cascade has questioned the causal role of this pathway. There is a growing appreciation that the pathogenesis of the illness is multifactorial with Amyloid Beta, Phosphorylated Tau (ptau), inflammation, mitochondrial dysfunction, calcium dyshomeostasis, heavy metal imbalances, and GSK-3 interact in a highly complex manner to provoke a selfsustaining spiraling cascade of pathology, driving disease progression. In the light of such complex pathology, the failure of drugs aimed a targeting single molecules is not surprising as such approaches are usually ineffective against other complex diseases with a multifactorial pathogenesis. Combination therapies or multi target drugs might be more effective in controlling such illnesses. The putative neuroprotective effects of Lithium are achieved via the positive modulation of numerous homeostatic mechanisms regulating autophagy, oxidative stress, inflammation, and mitochondrial dysfunction likely achieved by inhibiting GSK-3 and inositol-145 triphosphate. Data regarding efficacy in human trials and animal models of AD are mixed, but recent data using "microdose" lithium in mild cognitive impairment is encouraging, hence lithium could be a putative multi target treatment in these patients. However, additional well designed long-term trials are needed to confirm its efficacy and safety, given that long term use is necessary to achieve reasonable therapeutic benefit.

Overview

Integrity signals

Registry

Crossref · 10.2174/1567205013666160219113112

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 53

Metadata

Authors
Morris, G., & Berk, M.
Affiliations
Barwon Health (AU)
Venue
Current Alzheimer Research
Published
2016-06-02
Volume
13
Issue
8
Pages
853-861
ISSN
1567-2050 (ISSN-L)
OpenAlex
W2409746499
Cited by
53
References
0
Citations by year
2025: 2 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 1 · 2020: 10 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 3
FWCI
6.99
Type
journal article
Language
en
Open access
closed
Locations
  • Current Alzheimer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
lithium, Alzheimer's disease, GSK3 inhibition, multi-target drugs, combination therapy, amyloid-beta, phosphorylated tau, neuroinflammation, mitochondrial dysfunction, calcium dysregulation, autophagy, oxidative stress, inositol 1,4,5-trisphosphate, mild cognitive impairment, neuroprotection
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Lithium Compounds, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Putative Use of Lithium in Alzheimer's Disease. https://app.cochat.ai/papers/10.2174/1567205013666160219113112
The paper
Morris, G., & Berk, M. (2016). The Putative Use of Lithium in Alzheimer's Disease. Current Alzheimer Research. https://doi.org/10.2174/1567205013666160219113112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.